scholarly journals Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice

2020 ◽  
Author(s):  
Carolina Perdomo ◽  
Paola D’Ingianna ◽  
Javier Escalada ◽  
Salvatore Petta ◽  
Manuel Romero Gómez ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Metabolic Comorbidities

scholarly journals Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

2021 ◽  
Vol 51 (10) ◽  
pp. 1013-1025
Author(s):  
Katsutoshi Tokushige ◽  
Kenichi Ikejima ◽  
Masafumi Ono ◽  
Yuichiro Eguchi ◽  
Yoshihiro Kamada ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Evidence Based ◽  
Nonalcoholic Fatty Liver

scholarly journals Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

2015 ◽  
Vol 45 (4) ◽  
pp. 363-377 ◽  
Author(s):  
Sumio Watanabe ◽  
Etsuko Hashimoto ◽  
Kenichi Ikejima ◽  
Hirofumi Uto ◽  
Masafumi Ono ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Evidence Based ◽  
Nonalcoholic Fatty Liver

scholarly journals Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting

2017 ◽  
Vol 32 (4) ◽  
pp. 397-402 ◽  
Author(s):  
Luca Miele ◽  
Teresa De Michele ◽  
Giuseppe Marrone ◽  
Maria Antonietta Isgrò ◽  
Umberto Basile ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Predictive Value ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Severe Fibrosis

Background Liver fibrosis is the main determinant and predictor of the clinical course of nonalcoholic fatty liver disease (NAFLD). To date, a liver biopsy is still considered the gold standard for staging fibrosis. The aim of this study was to investigate the diagnostic accuracy of the commercial enhanced liver fibrosis (ELF) test manufacturer's cutoff value (≥9.8) in identifying severe fibrosis for adult patients with histologically confirmed NAFLD. Methods We tested the ELF test in a clinical practice, prospective cohort of 82 consecutive patients who consecutively underwent percutaneous liver biopsy. Results All stages of liver fibrosis were represented in our cohort, and severe fibrosis was present in 15 of 82 patients (18.3%). The stage of fibrosis was significantly associated with ELF score (Spearman's rho = 0.483, p<0.001). The commercial ELF test manufacturer's cutoff identified severe fibrosis with good sensitivity (86.7%; 95% confidence interval [95% CI], 0.69-1.04) and high specificity (92.5%; 95% CI, 0.86-0.99), with a positive predictive value of 72% and negative predictive value of 97%. Conclusions Our data could support the use of the ELF test in clinical practice.

scholarly journals Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice

2017 ◽  
Vol 15 (12) ◽  
pp. 1968-1971 ◽  
Author(s):  
Leah Avery ◽  
Catherine Exley ◽  
Stuart McPherson ◽  
Michael I. Trenell ◽  
Quentin M. Anstee ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Disease ◽  
Qualitative Study ◽  
Behavior Change ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lifestyle Behavior ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document